Transcode Therapeutics, Inc. — Director's Dealing 2021

Jul 9, 2021

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Transcode Therapeutics, Inc. (RNAZ)
CIK: 0001829635
Period of Report: 2021-07-08

Reporting Person: Dudley Robert Michael (Director, Chief Executive Officer, 10% Owner)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	843113	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (Right to Buy)	$0.091	2025-06-18	Common Stock (818852)		Direct

Footnotes

F1: Thirty-three percent (33%) of the Stock Options shall vest and become exercisable on the Vesting Commencement Date (January 1, 2020). Thereafter, the remaining sixty-seven percent (67%) of the Stock Options shall vest and become exercisable in 24 equal monthly installments on the last day of each such month following the first anniversary of the Vesting Commencement Date, provided the Optionee continues to have a Service Relationship with the Company on each vesting date.